Discontinued — last reported Q3 '24
Total Allocated To Reportable Segments — Operating income (loss)
Boston Scientific Total Allocated To Reportable Segments — Operating income (loss) increased by 6.1% to $1.35B in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 32.9%, from $1.02B to $1.35B. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates improved operational efficiency or higher sales volume within the core business segments, while a decrease suggests margin compression or declining demand in key product areas.
Detailed definition
This metric represents the aggregate operating profit or loss generated by all of the company's distinct reportable busi...
Peer comparison
This is comparable to 'Total Segment Operating Income' reported by other diversified medical device manufacturers, though variations exist based on how companies allocate corporate overhead and shared R&D costs.
bsx_segment_total_allocated_to_reportable_segments_operating_income_lossHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $949.00M | $859.00M | $827.00M | $847.00M | $941.00M | $942.00M | $1.01B | $940.00M | $1.01B | $1.02B | $1.13B | $1.27B | $1.35B |
| QoQ Change | — | -9.5% | -3.7% | +2.4% | +11.1% | +0.1% | +6.9% | -6.7% | +7.8% | +0.3% | +11.0% | +12.8% | +6.1% |
| YoY Change | — | — | — | — | -0.8% | +9.7% | +21.8% | +11.0% | +7.7% | +7.9% | +20.0% | +25.6% | +32.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's total allocated to reportable segments — operating income (loss)?
- Boston Scientific (BSX) reported total allocated to reportable segments — operating income (loss) of $1.35B in Q3 2024.
- How has Boston Scientific's total allocated to reportable segments — operating income (loss) changed year-over-year?
- Boston Scientific's total allocated to reportable segments — operating income (loss) increased by 32.9% year-over-year, from $1.02B to $1.35B.
- What does total allocated to reportable segments — operating income (loss) mean?
- The combined operating profit or loss generated by all of the company's individual business segments.